Comparative safety and sedation effectiveness of intranasal dexmedetomidine versus midazolam for preoperative anxiety reduction in pediatric surgical patients: an updated systematic review and meta-analysis Authors: Hany A Zaki, Hussam Elmelliti, Ahmed Shaban, Amira Shaban, Ali Elkandow, Mohamed Gafar Abdelrahim, Mohamed Ezzat Jawad, Mohamed F Abosamak, Eman E Shaban Published: 2026 ABSTRACT AbstractBackgroundRelieving pre-operative anxiety in children is a major concern for anesthesiologists. Midazolam has been the most commonly used sedative agent due to its long history of efficacy. However, it has been associated with complications, such as agitation, cognitive impairment, amnesia, and respiratory depression. For these reasons, other drugs, such as dexmedetomidine, have been explored as safe and effective alternatives in children undergoing surgery.ObjectiveTo evaluate the efficacy and safety of intranasal dexmedetomidine as compared to intranasal or oral midazolam in reducing preoperative anxiety in pediatric surgical patients.MethodsPubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant articles published from inception to January 2026. The search was limited to articles written in English and involved keywords and MeSH terms related to midazolam, dexmedetomidine, surgery, and children.ResultsNineteen randomized controlled trials with 1475 pediatric surgical patients were included. The pooled analysis revealed that intranasal dexmedetomidine was associated with significantly lower anxiety scores at or before induction (SMD: -1.10; 95% CI: -1.68 to -0.53; p = 0.0002), parental separation anxiety (SMD: -0.56; 95% CI: -0.99 to -0.12; p = 0.01), and mean heart rate (HR) (MD: -6.60 beats/min; 95% CI: -10.56 to -2.64; p = 0.001) compared to intranasal midazolam. However, intranasal dexmedetomidine was comparable to oral midazolam in terms of anxiety at or before induction (MD: -7.70; 95% CI: -18.89 to 3.59; p = 0.18), parental separation anxiety (RR: 1.13; 95% CI: 0.44 to 2.88; p = 0.80), and postoperative emergence agitation (RR: 0.22; 95% CI: 0.02 to 2.94; p = 0.25).ConclusionIntranasal dexmedetomidine is more effective than intranasal midazolam in reducing preoperative anxiety in children. No statistically significant difference was detected between intranasal dexmedetomidine and oral midazolam, but studies may have been underpowered to detect clinically important differences.Systematic review protocol registrationPROSPERO: CRD420251234972.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-03845-5.Keywords: Intranasal midazolam, Intranasal dexmedetomidine, Preoperative anxiety, Pediatric, Surgical patients Introduction Pediatric patients often present with varying degrees of anxiety during the preoperative period, which may be due to separation from their parents or the fear of injection and the operating theatre [1]. The anxiety can cause stress, tachycardia, agitation, or excessive crying, making the management of such patients difficult during anesthesia induction. Furthermore, anxiety can make the control of postoperative pain difficult, with research showing that patients with high levels of preoperative anxiety are highly susceptible to severe pain after surgery [2, 3]. Therefore, relieving pre-operative anxiety is a crucial concern for pediatric anesthesiologists. Over the years, several pharmacological and non-pharmacological techniques have been used to alleviate anxiety and promote compliance during the induction of anesthesia in children. These methods include the presence of parents, premedication sedatives, and training programs for children and their parents. Among the pharmacological options, midazolam is the most frequently used premedication, and research has shown that it is more effective than placebo or the presence of parents in minimizing anxiety and improving compliance during the induction of anesthesia [4, 5]. Nonetheless, reports show that midazolam is associated with increased adverse events, such as agitation, paradoxical reaction, and negative behavioral changes after surgery [6]. Moreover, only 70% of pediatric patients are reported to accept oral midazolam sufficiently [7]. For these reasons, other drugs and administration routes are being explored. One of the drugs being explored is dexmedetomidine, which is a highly specific α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties [8, 9]. Intranasal dexmedetomidine is increasingly being used due to its efficacy in sedation and enhanced bioavailability profile. Indeed, Yuen and colleagues found that in children aged 1–12 years of ASA physical status 1–2, intranasal 1 µg/kg dexmedetomidine induced sufficient sedation within 25 to 30 min and lasted for about 85 min with a modest reduction in heart rate (HR) and blood pressure (BP) [10]. However, a higher dose of dexmedetomidine would prolong the postoperative recovery time significantly, and it is less practical for shorter and minor surgeries. Previous systematic reviews and meta-analyses [11–16] have compared the efficacy and safety of dexmedetomidine versus midazolam across pediatric populations and surgical contexts. For instance, an updated meta-analysis with trial-sequence analysis found that intranasal dexmedetomidine was associated with higher incidence of satisfactory parental separation and reduced emergence agitation compared with oral midazolam [15]. Another meta-analysis of 11 randomized studies with 824 children found that intranasal dexmedetomidine was associated with better sedation effects at parental separation and anesthesia induction compared with oral midazolam [16]. However, these reviews have either included heterogeneous routes of administration or focused primarily on sedation scores without rigorously assessing preoperative anxiety. Therefore, this updated meta-analysis evaluated the safety and sedation effectiveness of intranasal dexmedetomidine versus intranasal midazolam in reducing preoperative anxiety among pediatric surgical patients. The review will also offer new clinical insights by incorporating recent studies and converting pooled estimates into clinically meaningful metrics, thus informing premedication choices in pediatric population. Methods Study design We conducted and reported a systematic review and meta-analysis strictly following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol for this systematic review and meta-analysis were prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number [CRD420251234972]. The registration includes the review objectives, inclusion/exclusion criteria, data sources, and planned analysis methods. The full protocol can be accessed at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251234972. Eligibility criteria For studies to be included in this meta-analysis, they had to meet the inclusion criteria outlined in Table 1. Moreover, only studies enrolling ≥ 10 participants per arm were included. This was to ensure that the pooled results were robust. Table 1Inclusion and exclusion criteriaCriterionIncludeExcludePopulation (P)Pediatric patients (< 18 years) undergoing surgical procedures under anesthesia or sedation.Adult patients (≥ 18 years).Intervention (I)Intranasal dexmedetomidine given as a premedication (of any dose and concentration)Dexmedetomidine administered via other routes (e.g., oral, intravenous, intramuscular, buccal, or sublingual), without specifying the data for intranasal separately.Comparator (C)Intranasal or oral midazolam administered as a premedication.Midazolam administered via other routes or combined with other pharmacological agents.Outcomes (O)Studies reporting preoperative anxiety and/or any of the following outcomes: Adverse events and hemodynamic outcomes.Studies not reporting preoperative anxiety or those reporting postoperative anxiety.Study Design (S)Randomized controlled trialsObservational studies (cohort, case-control, and cross-sectional studies), case reports, reviews, conference/poster abstracts, editorials, and/or meta-analyses.LanguageStudies authored in English or those that have an English translation.Non-English.Publication dateFrom inception to November 2025.- Inclusion and exclusion criteria Literature search and information sources A systematic online search for potential studies was conducted in PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception until December 2025. The search strategy was developed by the review team, with input from an author (E.E.S.) experienced in systematic review methodology and advanced database searching. It incorporated both database-specific controlled vocabulary (e.g., MeSH terms in PubMed) and free-text keywords, combined using Boolean operators (“AND” and “OR”). The strategy was adapted for each database using appropriate syntax and field tags. The search was iteratively refined to ensure comprehensiveness and accuracy. No publication date restrictions were applied, and all studies published from database inception to January 2026 were considered. To ensure completeness, grey literature sources, including ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), ProQuest Dissertations & Theses Global, and Research Square. Additionally, we hand-searched the bibliographies of previously published reviews, grey literature (dissertations and theses), and included studies to identify additional studies that might have been missed when carrying out the online search. The complete search strategies in each database are shown in the supplementary file (Appendix A). Data extraction and data items Two authors independently screened the full manuscripts of included studies and extracted the information required for review and analysis using a predesigned Excel spreadsheet. The information collected from each study included author names, study design, country, patient demographics (sample size, age, gender distribution, and American Society of Anesthesiologists (ASA) status), type of surgery, intervention details (dose, route of administration, and duration before anesthesia induction or surgery), anxiety assessment criteria, and measured outcomes. Differences in extracted data were resolved through consensus or by consulting a third author. Outcomes The primary outcome of this study was preoperative anxiety, which was evaluated as anxiety scores before anesthesia induction or parental separation anxiety. Anxiety score before induction was defined as the anxiety from premedication to anesthesia induction. The secondary outcomes were adverse events and preoperative hemodynamic outcomes, such as heart rate (HR), oxygen saturation (SpO2), and respiratory rate (RR). Adverse events referred to any side effect that occurred after premedication. Quality assessment Risk of bias within the included studies was assessed using the Cochrane’s risk of bias (RoB-2) tool embedded in the Review Manager software. Using the RoB-2 tool, studies were assigned low, high, or unclear risk of bias across the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. For the “other bias” criterion, we evaluated whether the studies had bias due to contamination (i.e., whether there was an overlap between the control and intervention groups) and generalizability (i.e., whether the study findings were generalizable to other settings). Data synthesis Statistical analyses were conducted using the Review Manager software (RevMan version 5.4.1; The Nordic Cochrane Center, The Cochrane Collaboration, 2014). Preoperative anxiety outcomes were pooled and summarized using the Mean Difference (MD) when studies used similar scales and standardized mean differences (SMD) with 95% confidence intervals (CIs) when studies used different but conceptually equivalent scales. For studies reporting anxiety outcomes using dichotomous data, risk ratios (RR) were used to pool and summarize the overall effect sizes. Other continuous data, such as HR, RR, and SpO2, were pooled using MD. Interstudy heterogeneity was assessed using the I2 statistic, with index values of 0–25%, 26–75%, and > 75% indicating low, moderate, and high heterogeneity, respectively [17]. Outcomes without heterogeneity (I2 = 0%) were pooled using a fixed effect model, and those with I2 > 0% were pooled using the DerSimonian-Laird random effects model. Moreover, for studies with multiple eligible intervention arms, the relevant groups were combined to avoid double-counting of participants. In cases where continuous data were reported using median and interquartile range or range, the mean and standard deviations (SD) were estimated using the formula presented by Wan and colleagues [18]. When studies reported median and interquartile range the mean and SD were estimated as follows: and , where Q1 is the first quartile, Q3 is the third quartile, n is the sample size, and is the inverse cumulative distribution function for the standard normal distribution. When studies reported median, minimum and maximum range the following formulas were employed: Random-effects meta-regression was conducted to examine the potential sources of heterogeneity for outcomes demonstrating substantial heterogeneity (I2 > 75%). The covariates selected for meta-regression included, dose of intranasal dexmedetomidine, timing of drug administration, type of anxiety assessment scale, and surgical setting. Regression coefficients and the corresponding p-values were used to determine the effects of each covariate on the observed interstudy heterogeneity. In addition, sensitivity analyses excluding studies with converted data were performed to test the robustness of pooled outcomes. The subgroup analyses according to the route of midazolam administration were pre-specified since the route of administration was expected to be an important source of heterogeneity, whereas meta-regression and sensitivity analyses were exploratory post-hoc analyses. The clinical relevance for pooled outcomes reported using MD and RR was assessed using the minimal clinically important difference (MCID). For RR, the probit transformation method was used to estimate MCID, with Cohen’s d calculated as d=|inverse_Φ(risk for experiment) – inverse_Φ(risk for control)| where Φ represents the cumulative distribution function, whereas the distribution method was used for outcomes using MD, where Cohen’s d was calculated as the MD between two groups divided by the pooled SD. Cohen’s d values of 0.2, 0.3, and 0.5 indicated small, medium, and large MCID, respectively [19]. For anxiety outcomes pooled using SMD, clinical significance was assessed by approximating the units of mYPAS, which was calculated as SMD × representative SD (~ 15). Reporting bias assessment For studies where data related to preoperative anxiety were missing, the corresponding authors were contacted via email to request the missing outcome. Studies where the authors did not respond in time to conduct this review were excluded. Certainty of evidence The GRADE assessment tool was used to evaluate the certainty of evidence for the pooled outcomes. For each outcome, the following domains were evaluated: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Risk of bias was examined using the Cochrane’s RoB-2 tool. Inconsistency was evaluated using the magnitude of I2 statistics, of which values of 0–25%, 26–75%, and > 75% indicated no, serious, or very serious inconsistency. Imprecision was determined based on the width of the 95% CI in relation to the line of effect, and publication bias was qualitatively analyzed according to the study sizes. The overall certainty of evidence was categorized as high, moderate, low, or very low. Results Search results Our preliminary database search yielded 1044 potential studies, with 599 identified in PubMed, 203 in Web of Science, 164 in CENTRAL, and 78 in Scopus. After screening these studies, we excluded 679 duplicates. The remaining studies had their titles and abstracts reviewed for relevance, but only 33 seemed relevant to our study objective. These 33 studies were screened against the eligibility criteria, of which only 19 were included. The reasons for excluding the remaining 14 studies were as follows: 4 involved pediatric patients undergoing non-surgical procedures, 2 were non-English, and 8 did not report preoperative anxiety outcome (Fig. 1). PRISMA flow diagram for study selection Characteristics of included studies A summary of the characteristics of the included studies is shown in Table 2. Of the 19 included studies, 12 compared intranasal dexmedetomidine with intranasal midazolam and 7 compared intranasal dexmedetomidine with oral midazolam. These studies enrolled a total of 1475 patients and were conducted in several countries, including India, Turkey, China, the United States, Sweden, and Oman. Several scales, including the parental separation anxiety scale (PSAS), behavior scale, facial image scale (FIS), and modified Yale preoperative anxiety scale (mYPAS), were used in evaluating preoperative anxiety at different time points. Table 2Summary of study characteristicsAuthor IDStudy designCountryPatient CharacteristicsType of surgeryInterventionComparatorAnxiety assessment scaleSample sizeM/FMean Age (SD)ASAMalineni et al.2017 [20]Double-blind RCTIndia6010/50IG: 2.8 (1.8)CG: 3.2 (2.2)I – IILower abdominal and limb surgeries1 ug/kg intranasal dexmedetomidine using 1 ml tuberculin syringe administered 45–60 min before being transferred to the OR.0.2 mg/kg intranasal midazolam4-point PSASAlam et al.2023 [21]Double-blind RCTIndia6048/12IG: 5.6 (2.7)CG: 5.8 (2.7)IElective surgeries1 ug/kg intranasal dexmedetomidine using a 1 ml insulin syringe.0.2 mg/kg intranasal midazolam using 1 ml insulin syringe.4-point behavior scale.Aich et al.2016 [22]Double-blind RCTIndia6039/21NRI – IIElective surgeries1 ug/kg intranasal dexmedetomidine using a 1 ml syringe 60 min before surgery.0.2 mg/kg intranasal midazolam using 1 ml syringe 60 min before surgery.4-point behavior scaleNeville et al.2016 [23]Double-blind RCTUnited States3825/13IG: 3.44CG: 3.15NRLaceration repairs2 ug/kg intranasal dexmedetomidine.0.4 mg/kg intranasal midazolammYPASGandhi et al.2023 [24]Prospective RCTIndia100NRNRI – IIElective surgeriesIntranasal dexmedetomidine 1 µg/kg (through needleless syringe) 30 min before surgeryIntranasal midazolam 0.2 mg/kg (through needleless syringe) 30 min before surgery.4-point PSASSaad et al.2020 [25]Prospective, double-blind RCTEgypt4829/19IG: 5.04 (1.49)CG: 5.13 (1.54)IAdenotonsillectomy surgery.Intranasal dexmedetomidine at 1 µg/kg given 45 min before inductionIntranasal midazolam at 0.2 mg/kg given 45 min before induction4-point behavior scale.Diwan et al.2020 [26]Prospective, double-blind RCTIndia6033/27IG: 59.13 (35.93monthsCG: 49.60 (18.97) monthsI – IIElective surgeriesIntranasal dexmedetomidine (1 µg/kg), 30 min before induction.0.2 mg/kg intranasal midazolam, 30 min before induction4-point behavior scale.Sivrikaya et al.2015 [27]Prospective, double-blind RCTTurkey7033/37IG: 4.42 (1.12)CG: 3.97 (1.44)IElective surgeries2 µg/kg intranasal dexmedetomidine, 30 min before induction0.2 mg/kg intranasal midazolam, 30 min before induction.4-point behavior scale and 3-point PSASDavis et al.2018 [28]Prospective, double-blind RCTIndia120NRIG: 4.53 (2.55)CG: 5.54 (2.82)I – IIElective surgeries1 mcg/kg of intranasal dexmedetomidine using a needleless 1 ml syringe0.2 mcg/kg of intranasal midazolam using a needleless 1 ml syringe.4-point PSASDangi et al.2021 [29]Double-blind RCTIndia10049/51IG: 7.4 (0.7)CG: 7.6 (0.9)IElective surgeriesIntranasal Dexmedetomidine at 1 µg/kg using a 3 ml syringe, 60 min before inductionintranasal Midazolam at 0.2 mg/kg using a 3 ml syringe, 60 min before induction4-point PSASLalwani et al.2025 [30]Double-blind RCTIndia4816/32NRI – IIDental proceduresIntranasal dexmedetomidine [1.5 µg/kg].Intranasal midazolam [0.25 mg/kg].FISSingla et al.2015 [31]Prospective, double-blind RCTIndia6031/29IG: 5.86 (0.40)CG: 5.91 (0.46)IElective surgeriesIntranasal dexmedetomidine 1 µg/kg, 30 min before induction.Intranasal midazolam 0.2 mg/kg, 30 min before induction4-point PSASSingh et al.2022 [32]RCTIndia10250/52NRIDental proceduresIntranasal 2 µg/ kg dexmedetomidine, 30 min before inductionOral 0.5 mg/kg midazolam, 30 min before induction4-point PSASYuen et al.2008 [33]Prospective, double-blind RCTChina9689/7IG: 6.1 (2.7)CG: 6.4 (3.0)I – IIElective surgeriesIntranasal dexmedetomidine at one ug/kg.0.5 mg/kg oral midazolam, up to a maximum 15 mg4-point behavior scale.Wang et al.2020 [34]RCTChina6031/29IG: 4.56 (0.59)CG: 4.79 (0.48)IDental proceduresIntranasal 2 µg/ kg dexmedetomidine, 30 min before induction0.5 mg/kg oral midazolam, 30 min induction4-point PSASKumar et al.2017 [35]Prospective, double-blind RCTIndia6034/26IG: 6.4 (2.3)CG: 5.5 (1.7)I – IIElective surgeriesIntranasal dexmedetomidine at 1 ug/kg.0.5 mg/kg oral midazolam4-point behavior scale.Cai et al. 2021 [36]Prospective, double-blind RCTChina129116/13IG: 4.3CG: 5.1I – IIElective surgeriesIntranasal 2 µg/ kg dexmedetomidine.0.5 mg/kg oral midazolammYPAS and PSASBromfalk et al.2020 [37]Double-blind RCTSweden8450/34IG: 4.2 (0.9)CG: 4.2 (1.0)I – IIENT surgeryIntranasal dexmedetomidine 2 µg/kg 40 min preoperativelyOral midazolam 0.5 mg/kg, 40 min preoperativelymYPASGhali et al.2011 [38]Prospective, double-blind RCTOman12062/58IG: 8.2 (1.4)CG: 8.1 (2.3)IAdenotonsillectomyIntranasal dexmedetomidine at 1 ug/kg, 60 min before induction.0.5 mg/kg oral midazolam, 60 min before induction.mYPASNR Not Reported, IG Intervention group (intranasal dexmedetomidine), CG Control group (Intranasal/oral midazolam), ASA American Society of Anesthesiologists, mYPAS modified Yale preoperative anxiety scale, PSAS Parental separation anxiety scale, FIS Facial image scale, RCT Randomized controlled trial Summary of study characteristics IG: 2.8 (1.8) CG: 3.2 (2.2) IG: 5.6 (2.7) CG: 5.8 (2.7) IG: 3.44 CG: 3.15 IG: 5.04 (1.49) CG: 5.13 (1.54) IG: 59.13 (35.93months CG: 49.60 (18.97) months IG: 4.42 (1.12) CG: 3.97 (1.44) IG: 4.53 (2.55) CG: 5.54 (2.82) IG: 7.4 (0.7) CG: 7.6 (0.9) IG: 5.86 (0.40) CG: 5.91 (0.46) IG: 6.1 (2.7) CG: 6.4 (3.0) IG: 4.56 (0.59) CG: 4.79 (0.48) IG: 6.4 (2.3) CG: 5.5 (1.7) IG: 4.3 CG: 5.1 IG: 4.2 (0.9) CG: 4.2 (1.0) IG: 8.2 (1.4) CG: 8.1 (2.3) NR Not Reported, IG Intervention group (intranasal dexmedetomidine), CG Control group (Intranasal/oral midazolam), ASA American Society of Anesthesiologists, mYPAS modified Yale preoperative anxiety scale, PSAS Parental separation anxiety scale, FIS Facial image scale, RCT Randomized controlled trial Intranasal dexmedetomidine versus intranasal midazolam A total of seven studies compared the effects of intranasal dexmedetomidine versus intranasal midazolam on anxiety before anesthesia induction. The pooled results from these studies revealed that children premedicated with intranasal dexmedetomidine had significantly lower anxiety scores before induction than those premedicated with intranasal midazolam (SMD: -1.10; 95% CI: -1.68 to -0.53; p = 0.0002, I2 = 85%) (Fig. 2). The pooled SMD of -1.10 corresponded to approximately − 16.5 mYPAS points (Table 3), suggesting that the observed difference was clinically meaningful. A sensitivity analysis excluding three studies [22, 24, 26] with converted data did not alter the statistical significance and direction of effect, suggesting that this outcome was robust. Forest plot showing anxiety scores before anesthesia induction between intranasal dexmedetomidine and intranasal midazolam groups Table 3Clinical relevance of pooled estimates for intranasal dexmedetomidine versus intranasal midazolamOutcomeSMD (95% CI)p-valueApproximated mYPAS pointsInterpretationAnxiety before anesthesia induction-1.10 (-1.68 to -0.53)0.0002-16.5Clinically meaningful reduction in preoperative anxietyParental separation anxiety-0.56 (-0.99 to -0.12)0.01-8.4Moderate but clinically meaningful reduction in preoperative anxiety. Clinical relevance of pooled estimates for intranasal dexmedetomidine versus intranasal midazolam Similarly, a meta-analysis of six studies demonstrated significantly lower parental separation anxiety scores in the intranasal dexmedetomidine group compared to the intranasal midazolam group (SMD: -0.56; 95% CI: -0.99 to -0.12; p = 0.01) (Fig. 3). When converted to approximate units of mYPAS, this effect corresponded to -8.4 mYPAS points (Table 3), indicating a clinically relevant decrease in parental separation anxiety. However, the pooled results were heterogeneous (I2 = 80%). The sensitivity analysis excluding two studies [24, 26] with converted data did not show any change in statistical significance and direction of effect, indicating the robustness of this finding. Forest plot showing parental separation anxiety between intranasal dexmedetomidine and intranasal midazolam groups Regarding the effects on hemodynamic outcomes, the pooled results showed no significant difference between the two groups in terms of preoperative SpO2 (MD: -0.06; 95% CI: -0.25 to 0.14; p = 0.58, I2 = 0%) (Figure S1) and RR (MD: 0.10; 95% CI: -2.02 to 2.22; p = 0.92, I2 = 75%) (Figure S2). However, patients receiving intranasal DEX demonstrated significantly lower preoperative HR than those receiving intranasal midazolam (MD: -6.60 beats/min; 95% CI: -10.56 to -2.64; p = 0.001, I2 = 92%) (Figure S3). All forest plots for secondary outcomes (Figures S1–S5) and the corresponding summary tables (Tables S1–S2) are provided in Appendix C (Supplementary Material). The majority of included studies did not report the incidence of adverse events; thus, the safety of these premedications was narratively synthesized. Neville et al. [23] reported two adverse events in patients premedicated with intranasal midazolam, with one patient displaying several emesis episodes, and one falling several times due to unsteadiness after laceration repair. On the other hand, Sivrikaya et al. [27] reported that the incidence of postoperative emergence agitation was significantly lower in the intranasal midazolam group than in the intranasal dexmedetomidine group for the first 15 min. However, the difference was statistically and clinically comparable after the first 15 min. Intranasal dexmedetomidine versus oral midazolam A meta-analysis of two studies demonstrated no significant difference between intranasal dexmedetomidine and oral midazolam in anxiety score before anesthesia induction (measured using the mYPAS) (MD: -7.70; 95% CI: -18.89 to 3.59; p = 0.18, I2 = 87%) (Fig. 4). However, the distribution method yielded an absolute Cohen’s d value of 0.84 (Table 4), which corresponds to a large MCID. This finding suggests that intranasal dexmedetomidine may substantially decrease anxiety scores before induction compared with oral midazolam. Forest plot showing anxiety scores before anesthesia induction between intranasal dexmedetomidine and oral midazolam groups Table 4Clinical relevance of pooled estimates for intranasal dexmedetomidine versus oral midazolamOutcomePooled Effect Sizep-valueAbsolute Cohen’s dInterpretationAnxiety before anesthesia inductionMD: -7.70 (-18.89 to 3.50)0.180.84Large MCIDParental separation anxietyRR: 1.13 (0.44 to 2.88)0.800.02Not clinically relevant Clinical relevance of pooled estimates for intranasal dexmedetomidine versus oral midazolam The pooled results also showed no significant difference between the two groups in anxiety at parental separation (RR: 1.13; 95% CI: 0.44 to 2.88; p = 0.80, I2 = 0%) (Fig. 5). Furthermore, the Cohen’s d calculated using the probit transformation method was 0.02, which indicates that the difference between the groups is extremely small and not clinically significant. Forest plot showing parental separation anxiety between intranasal dexmedetomidine and oral midazolam groups Notably, the pooled results revealed that preoperative HR was significantly lower in the intranasal dexmedetomidine group than in the oral midazolam group (MD: -11.81 beats/min; 95% CI: -13.51 to -10.10; p < 0.00001, I2 = 0%) (Figure S4). A safety analysis of data from three studies also showed no significant difference in the incidence of postoperative emergence agitation between pediatric patients receiving intranasal dexmedetomidine and those receiving oral midazolam (RR: 0.22; 95% CI: 0.02 to 2.94; p = 0.25, I2 = 78%) (Figure S5). Meta-regression analyses Meta-regression analyses were performed to examine the potential sources of the high interstudy heterogeneity observed across outcomes for intranasal dexmedetomidine versus intranasal midazolam (Table 5). For anxiety scores before induction, none of the examined covariates, including dose of dexmedetomidine, timing of administration, anxiety scale, or surgical setting, were significant sources of heterogeneity. However, the dose of intranasal dexmedetomidine accounted for approximately 28% of interstudy variance. Table 5Meta-regression analysesOutcomeCovariateRegression coefficientp-valueResidual I2Anxiety scores before inductionDose of intranasal dexmedetomidine0.500.0880%Timing of administration0.150.6888%Anxiety assessment scale0.120.7988%Surgical setting0.330.6588%Parental separation anxietyDose of intranasal dexmedetomidine1.050.00549%Timing of administration0.390.3880%Anxiety assessment scale-0.940.000225%Heart rateDose of intranasal dexmedetomidine2.680.2988%Timing of administration-2.190.3993%Surgical setting8.390.0175% Meta-regression analyses For parental separation anxiety, the dose of intranasal dexmedetomidine and the anxiety assessment scale emerged as significant sources of heterogeneity. However, the timing of administration did not significantly explain heterogeneity for this outcome. On the other hand, the surgical setting significantly explained the heterogeneity observed for the heart rate outcome. Other covariates (dose of intranasal dexmedetomidine or timing of administration) did not significantly explain heterogeneity. Given the limited number of studies, we were unable to investigate the heterogeneity observed in the outcomes for intranasal dexmedetomidine versus oral midazolam. Certainty of evidence In the comparison between intranasal dexmedetomidine and intranasal midazolam, we observed that the certainty was high for anxiety scores before induction, moderate for parental separation anxiety, oxygenation, and HR outcomes, and very low for respiratory rate. Overall, heterogeneity and wide 95% CIs were the main reasons for downgrading the certainty of evidence. When comparing intranasal dexmedetomidine with oral midazolam, the certainty rating was very low for anxiety scores at or before induction and postoperative agitation, moderate for parental separation anxiety, and high for HR outcomes. The details for certainty of evidence are shown in Tables 6 and 7 in Appendix B (Supplementary Material). Publication bias Although we had planned to conduct a formal publication bias assessment using funnel plots and Egger’s test, this was not possible because none of the pooled outcomes had ≥ 10 studies, which is the recommended minimum for this assessment. Risk of bias outcomes Figure 6 shows a summary of the risk of bias assessment. From the evaluation, it is evident that several studies had a high risk of bias in the “other bias” criterion. This is because the studies were conducted in single medical institutions, limiting their generalizability to other populations or settings. Risk of bias summary Discussion Children undergoing surgical procedures can experience considerable anxiety and distress during the preoperative period, which can cause a negative response postoperatively. Therefore, premedication is needed to overcome anxiety, allow ease of separation from parents, and improve acceptance of needle prick before the induction of anesthesia. Among the various premedications available, midazolam has been the most commonly used, but it has been associated with respiratory depression and increased adverse events, such as agitation, paradoxical reaction, and negative behavioral changes after surgery [6, 39, 40]. In the wake of these disadvantages, dexmedetomidine has emerged as an alternative premedication for children undergoing surgery. Therefore, the present meta-analysis compared the efficacy and safety of intranasal dexmedetomidine versus intranasal or oral midazolam in reducing preoperative anxiety. In this meta-analysis, we found that pediatric patients premedicated with intranasal dexmedetomidine had significantly lower anxiety scores before anesthesia induction and during parental separation than those premedicated with intranasal midazolam. The observed SMD of -1.10 for anxiety scores before anesthesia induction corresponds to an approximate reduction of 16.5 mYPAS points, suggesting that intranasal dexmedetomidine provides a significant and clinically relevant reduction in preoperative anxiety compared with intranasal midazolam. This finding compares favorably with a previous meta-analysis, which reported easier child-parent separation with the administration of intranasal dexmedetomidine compared to midazolam and other sedatives [41]. This reduced preoperative anxiety in children receiving intranasal dexmedetomidine might be attributed to the different mechanisms of action between midazolam and dexmedetomidine. Unlike midazolam, which primarily enhances GABAergic inhibition, dexmedetomidine acts on central α2 receptors, resulting in electroencephalogram (EEG) activity similar to that of regular sleep [42]. This results in anxiolytic effects, sedation and analgesia without excessive drowsiness [43]. In contrast, the pooled results showed no significant difference between intranasal dexmedetomidine and oral midazolam in terms of anxiety scores before induction and parental separation anxiety. This finding suggests that the administration route might influence the anxiolytic effects of premedications, with the slower and more gradual onset of oral midazolam likely to produce a steadier anxiolytic effect than intranasal midazolam. However, one of the pooled studies reported that children premedicated with intranasal dexmedetomidine had significantly lower preoperative anxiety levels than those premedicated with oral midazolam [38]. Moreover, the pooled effect size corresponded to a large MCID, suggesting that intranasal dexmedetomidine may substantially lower anxiety scores compared with oral midazolam. This contradictory finding calls for further research to establish the anxiolytic effects of intranasal dexmedetomidine and oral midazolam in the preoperative period. Nevertheless, intranasal dexmedetomidine might still be preferred over oral midazolam because the intranasal route is a relatively noninvasive, convenient, and easy way administering premedications, as it does not require patient cooperation as would be the case for swallowing medication in the oral route. Research has also shown that the intranasal route has a faster onset and reduces the first-pass metabolism [44, 45]. Another significant finding of this meta-analysis was that the mean HR was considerably lower in children premedicated with intranasal dexmedetomidine than those premedicated with intranasal or oral midazolam. This finding was expected as dexmedetomidine is known to cause decrease in sympathetic outflow and circulating catecholamine levels [46]. However, despite HR being lower in patients receiving dexmedetomidine, all the included studies showed a mean HR that was within the normal range, and none reported any incidence of bradycardia, suggesting that intranasal dexmedetomidine is a safe premedication. Moreover, the mean SpO2 and RR were comparable between the two groups, meaning intranasal dexmedetomidine does not increase the risk of oxygen desaturation and respiratory distress compared to intranasal midazolam. Recently, remimazolam, a short-acting benzodiazepine, has emerged as a promising agent for anesthesia and sedation in pediatric and adultpopulations. Since its approval, growing evidence has shown that remimazolam offers superior hemodynamic stability, rapid emergence from anesthesia, and minimal respiratory depression compared to traditional anesthetic agents such as propofol [47–49]. Moreover, the current evidence base suggests that remimazolam can result in reduced preoperative anxiety and postoperative delirium in pediatric patients [50]. However, further research is required to determine its superiority over other benzodiazepines, such as midazolam and dexmedetomidine. Limitations The findings of this meta-analysis should be interpreted cautiously due to some inherent limitations. First, the lack of a significant difference between intranasal dexmedetomidine and oral midazolam might be due to the potential for route confounding. Therefore, the absence of statistical difference in these comparisons should not be interpreted as evidence of equivalence, rather they should be viewed as hypothesis-generating. Second, significant heterogeneity was observed in several pooled outcomes, highlighting possible variations in patient demographics, type of surgeries, type of anesthesia used for induction, and the dose of premedications. This variability might have limited the precision and generalizability of the pooled effect sizes. Second, the majority of included studies were conducted in one country (India). This overrepresentation of one country might have introduced geographical bias, potentially skewing the pooled estimates and limiting the generalizability of the results to other populations or settings. The geographic bias may have influenced the pooled estimates due to differences in clinical practice patterns, healthcare infrastructure, and patient characteristics [51]. Third, due to a small number of studies (i.e., fewer than 10 studies) in the pooled outcomes, we could not perform a publication bias assessment. This might have led to the overestimation of the effect size since small studies with null or unfavorable findings may be underrepresented. Fourth, we intentionally omitted records published in languages other than English, which may have introduced selection bias. Finally, due to the inconsistent reporting of adverse events, the safety evaluation of intranasal dexmedetomidine and intranasal midazolam was made through narrative synthesis. This limited us from making convincing conclusions regarding their safety. Nevertheless, existing literature has provided important evidence on the safety profile of intranasal dexmedetomidine in pediatric patients. For instance, a meta-analysis investigating the effects of dexmedetomidine in children undergoing magnetic resonance imaging found consistently substantial heterogeneity in the pooled outcomes, specifically regarding adverse events such as hypotension, bradycardia, and desaturation [52]. Conclusion Intranasal dexmedetomidine is more effective than intranasal midazolam in reducing preoperative anxiety and easing child-parent separation, without increasing the risk of respiratory distress. In contrast, the pooled results revealed no statistically significant difference between intranasal dexmedetomidine and oral midazolam. These findings suggest that intranasal dexmedetomidine can be considered as an effective alternative for premedication in children undergoing surgical procedures. However, further research is required to determine whether the route of administration can influence clinical outcomes. Supplementary Information Supplementary Material 1 Acknowledgements Not Applicable. Abbreviations American Society of Anesthesiologists Blood Pressure Cochrane Central Register of Controlled Trials Confidence Interval Control Group Dexmedetomidine Electroencephalogram Ear, Nose, and Throat Facial Image Scale Heart Rate Inconsistency Index Intervention Group Mean Difference Medical Subject Headings Modified Yale Preoperative Anxiety Scale Operating Room Population Post-Anesthesia Care Unit Postoperative Nausea and Vomiting Parental Presence Preferred Reporting Items for Systematic Reviews and Meta-Analyses International Prospective Register of Systematic Reviews Parental Separation Anxiety Scale Randomized Controlled Trial Risk Ratio Cochrane Risk-of-Bias Tool Study Design Standard Deviation Standardized Mean Difference Peripheral Oxygen Saturation Respiratory Rate Authors’ contributions H.A.Z: conceptualization and review protocol development; H.E, AM.S, E.E.S and AH.S did the quality assessment and statistical analysis; H.E, H.A.Z did the data extraction; A.E, M.E.J, M.G.A, M.F.A and E.E.S wrote up the results and prepared the draft manuscript; H.A.Z and M.F.A revised the draft manuscript. All authors have approved the manuscript for publication. Funding The authors received no financial support for this article. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.